HIF1A and melanoma: In fact, several HIF-1α inhibitors that are in clinical trials (for example, against melanoma, breast cancer and GBM), used in combination with chemotherapy, result in increased tumour responsiveness to treatment and a reduced tumour progression rate [65,66].